Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectus BiosystemsASX:VBS 12 EV-to-EBITDA is 3.96 as of Sep. 12, 2026. GuruFocus rates ASX:VBS with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 403 Biotechnology companies, Vectus Biosystems ranks better than 70.22% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vectus Biosystems's enterprise value is A$6.36 Mil.
Vectus Biosystems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.61 Mil. Therefore, Vectus Biosystems's EV-to-EBITDA for today is 3.96.
The historical rank and industry rank for Vectus Biosystems's EV-to-EBITDA or its related term are showing as below:
ASX:VBS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3.96
Current: 3.96
During the past 11 years, the highest EV-to-EBITDA of Vectus Biosystems was 3.96. The lowest was 0.00. And the median was 0.00.
ASX:VBS's EV-to-EBITDA is ranked better than 70.22% of 403
companies
in the Biotechnology industry
Industry Median: 13.21
vs ASX:VBS: 3.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vectus Biosystems's PE Ratio (TTM) for today is calculated as:
Vectus Biosystems's share price for today is A$0.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Vectus Biosystems's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VBS vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Vectus Biosystems's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectus Biosystems EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectus Biosystems's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vectus Biosystems's EV-to-EBITDA falls into.
Vectus Biosystems's current Enterprise Value is A$6.36 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectus Biosystems's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$1.61 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectus Biosystems (ASX:VBS) has a EV-to-EBITDA of 3.96 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vectus Biosystems. According to the industry distribution chart, Vectus Biosystems ranks #120 out of 403 companies in the Biotechnology industry, placing it in the top 29.8%.
Is Vectus Biosystems' EV-to-EBITDA too high?
Vectus Biosystems' current EV-to-EBITDA is 3.96. The Biotechnology industry median EV-to-EBITDA is 13.21. Vectus Biosystems' value of 3.96 is 70% below this industry median. Based on the distribution chart, Vectus Biosystems ranks #120 out of 403 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vectus Biosystems has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectus Biosystems ranks #120 out of 403 companies for EV-to-EBITDA. This puts Vectus Biosystems in the upper half of its industry. The industry median EV-to-EBITDA is 13.21. Vectus Biosystems' value of 3.96 is 70% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.21, based on 403 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectus Biosystems's current EV-to-EBITDA of 3.96 is 70% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vectus Biosystems. For the Biotechnology industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectus Biosystems's current EV-to-EBITDA is 3.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current EV-to-EBITDA of 3.96. The current EV-to-EBITDA is 3.96 and 70% below the Biotechnology industry median of 13.21. Vectus Biosystems' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current EV-to-EBITDA is 3.96 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
12GF Score
Get the complete analysis for ASX:VBS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VBS has been successfully added to your 
